Oncobiologics Profit Margin 2015-2021 | OTLK
Current and historical gross margin, operating margin and net profit margin for Oncobiologics (OTLK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Oncobiologics net profit margin as of June 30, 2021 is 0%.
|Oncobiologics Annual Profit Margins
|Oncobiologics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.